

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.


Licensee 1. St. Joseph Regional Medical Center, Inc. 2. 504 Sixth Street Lewiston, ID 83501		In accordance with letter dated February 18, 2022; and E-mail dated May 19, 2022 with attachments 3. License No.: 11-27371-01 is amended in its entirety to read as follows:	4. Expiration Date: March 31, 2023 5. Docket No.: 030-32211 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300	7. Chemical and/or physical form A. Any B. Any C. Any	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed C. 600 millicuries total	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200. C. For any use permitted by 10 CFR 35.300.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 11-27371-01

Amendment No. 19

Docket or Reference No.:
030-32211

- | | | | |
|---|--|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| D. Any byproduct material permitted in 10 CFR 35.400 | D. Sealed Sources (3M, Model 6500 Series; Amersham, Model 6702; 6711; 6733; CDCS.J3; SIAK.3158; BEBIG, Model 125.S06; Best Industries, Model 2300; 81-01; International Brachytherapy, Model 103L; 125IL; IsoStar Texas, Model IS-125; Isotope Products Laboratories, Model 67-6500 Series; 67-800 Series; 67-820 Series; North American Scientific, Model MED-3631; MED-3633; Syncor/Cardinal Health, Model BT-125-1; Theragenics, Model 200) | D. 2 curies total | D. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| E. Strontium-90 | E. Sealed Sources (Amersham, Model 0922 ML) | E. 30 millicuries per source and 30 millicuries total | E. For storage only. |
| F. Uranium- depleted in Uranium-235 | F. Metal | F. 999 kilograms total | F. For use as shielding in a linear accelerator. |
- 

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 11-27371-01

Amendment No. 19

Docket or Reference No.:
030-32211**CONDITIONS**

10. Licensed material may be used or stored only at the licensee's facilities located at St. Joseph Regional Medical Center, 415 Sixth Street, Lewiston, Idaho.
11. A. The Radiation Safety Officer (RSO) for this license is Dan Dugan, MS, DABR.
- B. The Associate Radiation Safety Officer (ARSO) for this license is William David Knight.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D., D.O., etc.)</u> | <u>Material and Use</u> |
|---|---|
| Dallen Ben Ashby, M.D. | 35.100, 35.200 |
| Robert Kenneth Fairbanks, M.D. | 35.200, 35.300, 35.400 |
| Paul Sanchirico, M.D. | 35.100, 35.200, oral administration of sodium iodide in quantities less than or equal to 33 millicuries |
| Gregory R. Spurling, M.D. | 35.100, 35.200 |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 11-27371-01

Docket or Reference No.:
030-32211

Amendment No. 19

C. The following individuals are authorized users for nonmedical uses as indicated:

Non-Medical Use

Douglas Heidorn, Ph.D.

Paul Sanchirico, M.D.

Material and Use

Cesium-137 for functionality tests of instruments

Depleted uranium as shielding in a linear accelerator

13. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee, except as specifically authorized.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 11-27371-01

Amendment No. 19

Docket or Reference No.:
030-32211

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated October 3, 2012 excluding procedures(ML12290A673)
- B. E-mail with attachments dated October 12, 2012 (ML12290A737)
- C. Emails with attachments dated March 18, 2013 excluding procedures (ML13078A146)
- D. Letter dated October 24, 2016 (ML16313A036)
- E. Letter dated June 10, 2020 (ML20177A166)
- F. E-mail dated August 18, 2020 with attachment (ML20232C156)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: May 19, 2022By: _____
Latischa M. Hanson
Region IV